A 23-year-old woman developed ischemic stroke (IS) 8 to 12 hours after ingestion of sumatriptan (ST) and then developed mucosal bleeding secondary to acute thrombocytopenia likely due to dipyridamole (DP) on the 10th day poststroke. Sumatriptan-associated IS and DP-induced thrombocytopenia are rare events in themselves and their sequential occurrence in the same patient is quite exceptional. We compare our case to other similar cases in the literature.
Agosti RM5HT1F- and 5HT7-receptor agonists for the treatment of migraines. CNS Neurol Disord Drug Targets. 2007;6(4): 235-237.
2.
Kim HH, Liao JKTranslational therapeutics of dipyridamole. Arterioscle Thromb Vasc Biol. 2008;28(3):S39-S42.
3.
Luman W., Gray GSAdverse reactions associated with sumatriptan. Lancet. 1993;341(8852):1091-1092.
4.
Jayamaha JE, Street MKFatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan . Intensive Care Med. 1995;21(1):82-83.
5.
Meschia JF, Malkoff MD, Biller J.Reversible segmental cerebral arterial vasospasm and cerebral infarction. Possible association with excessive use of sumatriptan and midrin. Arch Neurol. 1998;55(5):712-714.
6.
Pradalier A. , Lutz G., Vincent D.Transient global amnesia, migraine, thalamic infarct, dihydroergotamine, and sumatriptan. Headache. 2001;40(4):324-327.
7.
Vijayan N., Peacock JHSpinal cord infarction during the use of zolmitriptan: a case report. Headache. 2000;40(1):57-60.
8.
Singhal AB, Caviness VS, Begleiter AF, Mark EJ, Rordorf G., Koroshetz WJCerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology. 2002; 58(1):130-133.
9.
O’Quinn S., Davis RL, Gutterman DL, Pait GD, Fox AWProspective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. Cephalalgia. 1999;19(4):223-231.
10.
Hall GC, Brown MM, Mo J., MacRae KDTriptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology. 2004;62(4):563-568.
11.
Tepper SJ, Cady R., Dodick D., et al. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study. Headache. 2006;46(1):115-124.
12.
Meredith JT , Wait S., Brewer KLA prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med . 2003;21(3):173-175.
13.
Rothner AD, Wasiewski W., Winner P., Lewis D., Stankowski J.Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache. 2006;46(1):101-109.
14.
Edvinsson L. , Uddman E., Wackenfors A., Davenport A., Longmore J., Malmsjö M.Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect. Clin Sci. 2005;109(3):335-342.
15.
George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998;129(11):886-890.
16.
Swisher KK, Li X., Vesely SK, George JNDrug-induced thrombocytopenia: an updated systematic review, 2008. Drug Saf. 2009;32(1):85-86.
17.
Kaufman DW, Kelly JP, Johannes CB, et al. Acute thrombocytopenic purpura in relation to the use of drugs . Blood. 1993;82(9):2714-2718.
18.
Miyakis S., Lockshin MD, Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306.
